Skip to content
TrialMatch
Sign up
Recruiting Phase 1 / Phase 2

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC

Condition
Non-Small-Cell Lung Cancer
Tested
Vebreltinib, PLB1004
Sponsor
Avistone Biotechnology Co., Ltd.

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 9

  • Minimum age: 18 years
  • Study condition: Non-Small-Cell Lung Cancer
  • Ability to understand and willingness to sign a written informed consent document.
  • Aged at least 18 years old.
  • Histologically or cytologically confirmed locally advanced or metastatic NSCLC (stage IIIB\~IV).
  • EGFR mutations, including exon 19 deletion and exon 21 L858R.
  • C-Met overexpression and/or c-Met amplification confirmed after treatment with EGFR-TKI.
  • At least one measurable lesion as defined by RECIST V1.1.
  • ECOG performance status 0 to 1.

Exclusion 4

  • Previous treatment with MET inhibitors or HGF-targeted therapy.
  • There are mutations of ALK or ROS1.
  • Have symptomatic and neurologically unstable central nervous system (CNS) metastases or CNS disease that requires increased steroid doses for control.
  • Pregnant or nursing women.

Where

1 site, 1 recruiting

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.